Vaccinations are effectively reducing the spread of COVID-19 in the U.S.

While social distancing and masks have been the main tools to limit the spread of COVID-19 and "flatten the curve," highly effective (90%+) vaccines have changed the dynamics entirely. By delivering the available vaccines to the most vulnerable populations at an accelerated rate, the United States has been able to drastically reduce the spread of the virus. The animated visualization below shows how vaccinating even a small portion of a population can significantly slow the spread of a virus. These effects multiply as the percentage of the population that has been vaccinated continues to increase.

While still a concern, public attitude towards receiving the vaccination is gaining acceptance.

While the three vaccinations currently approved by the Emergency Use Act are touting an incredible 90% or greater effectiveness, some still have reservations about receiving them. While these concerns are understandable, they have a negative impact on the battle against COVID-19. Statistics from the Kaiser Family Foundation show that only 55% of people in the United States want to receive a vaccine as soon as possible. That said, the trends are positive. Since December 2020, the percentage of people who would receive a vaccine as soon as possible has nearly doubled, climbing from roughly 30% to 55%.

Vaccine distribution has successfully focused on the most vulnerable populations.

In order to maximize the impact of vaccines in reducing hospitalizations and deaths due to COVID-19, distribution has focused largely on the elderly. Through Innovu's employer data, we see that their members vaccine distribution follows along this trend. As most working populations are below the initial "most vulnerable" demographic of 65+ years of age, we see a lower percentage administered to those groups.

Medical costs for COVID-19 treatment rise and fall with the infection rate.

Over the past year, the average amount per COVID-19 admission has been roughly $145,000, based on Innovu's data. However, that amount appears to be contingent on the virus's current rate of reproduction. The chart below shows that the cost per admission changes, increasing and decreasing, in step with the spread of the virus{8}. The highest COVID-19 infection numbers were seen in January 2021 and have dropped dramatically since, largely due to the vaccines. Innovu expects that as admissions data is analyzed in the coming months, a similar downward trend in costs will be observed through the first quarter of the year.

COVID-19 vaccines are covered by the government, but administrative fees are not.

The federal government is covering the cost of all COVID-19 vaccines, but providers can still charge employers administration fees.[9] Innovu's data shows that administration costs average about $20 per member under Rx, and are slightly higher, at $25 per member, under medical. Additionally, Medicare vaccine shot payments are $26.94 for the first shot, $28.39 for the second; or $28.39 for single dose. These administrative costs can be unexpected for employers, given that in many cases they exceed the cost of the vaccine itself. In fact, insurance is not required to receive the vaccine. As of March 15th, 2021 Medicare now pays $40 per COVID-19 shot. ($80 for 2-doses).  Innovu expects that commercial carriers will increase the costs for the shot to mirror Medicare reimbursements.

The Pfizer, Moderna, and Johnson & Johnson vaccines have had a tremendous impact in limiting the spread of COVID-19. Vaccine distribution have successfully been administered to the  most vulnerable populations. helping to reduce overall hospitalizations and deaths. Cost of treatment has been rising and falling with the overall COVID-19 infection rate. While the federal government is covering the cost of the vaccine for the entire population, this does not cover administration costs that can be billed by providers.